AI-Driven Developability Assessment for Scalable Protein and Enzyme Manufacturing

Predict Protein Manufacturability Before Scale-Up

A protein with excellent biological activity is not always suitable for commercial manufacturing.

Many promising protein candidates fail during development because they are difficult to express, unstable during production, prone to aggregation, or challenging to purify.

Identifying these risks early can significantly reduce development time, manufacturing costs, and technical uncertainty.

Neoncorte Bio provides AI-driven protein manufacturability prediction to help organizations evaluate and optimize protein candidates before large-scale experimental investment.

Application Areas

AI-Driven Protein Manufacturability prediction
  • Industrial Enzyme Development

    Evaluate enzyme candidates before fermentation process development and commercial production.
    Benefit: Lower development risk and improved manufacturing efficiency.
  • Therapeutic Protein Development

    Assess developability during early-stage biologic discovery and lead optimization.
    Benefit: Better candidate selection before costly development phases.
  • Synthetic Biology

    Screen engineered proteins intended for scalable biological production platforms.
    Benefit: Faster platform development and reduced engineering cycles.
  • Specialty Biocatalysis

    Evaluate industrial enzymes designed for chemical synthesis and biomanufacturing.
    Benefit: More efficient transition from laboratory discovery to industrial production.
  • Research Reagents & Diagnostics

    Optimize proteins intended for commercial reagent manufacturing and analytical applications.
    Benefit: Improved production consistency and supply reliability.
AI-Driven Protein Manufacturability prediction

Why Manufacturability Prediction Matters

Late-stage manufacturing issues can delay commercialization and increase development costs.
Common challenges include:
  • Low recombinant expression
  • Protein aggregation
  • Poor folding efficiency
  • Limited stability
  • Difficult purification
  • Low production yield
  • Scale-up failures
  • Process variability
  • Early prediction enables informed decision-making and more efficient protein engineering strategies.

AI-Driven Developability Assessment

Neoncorte Bio combines artificial intelligence, structural biology, and protein engineering expertise to evaluate multiple characteristics influencing manufacturability.
Our assessment may include analysis of:
  • Sequence composition
  • Structural stability
  • Aggregation propensity
  • Solubility
  • Folding characteristics
  • Expression potential
  • Surface properties
  • Physicochemical features
  • Mutation opportunities
The goal is to prioritize protein variants with a higher likelihood of successful manufacturing while identifying opportunities for engineering improvements.

Protein Properties We Evaluate

Depending on project objectives, Neoncorte Bio can assess factors including:
  • Recombinant expression potential
  • Protein stability
  • Thermostability
  • pH stability
  • Solubility
  • Aggregation propensity
  • Folding efficiency
  • Structural robustness
  • Manufacturability risks
  • Sequence optimization opportunities
AI-Driven Protein Manufacturability prediction

What Neoncorte Bio Delivers

  • AI-driven protein manufacturability prediction
  • Protein developability assessment
  • Sequence and structure analysis
  • Risk identification for scalable production
  • Engineering recommendations
  • Multi-property optimization strategies
  • Confidential B2B consulting and development partnerships

Who We Work With

  • Biotechnology companies
  • Pharmaceutical developers
  • Industrial enzyme manufacturers
  • CDMOs and CROs
  • Synthetic biology startups
  • Diagnostic reagent companies
  • Agricultural biotechnology firms
  • Specialty chemical manufacturers
Frequently Asked Questions (FAQs)

Neoncorte Bio

Where AI Meets Biotechnology
Neoncorte Bio is at the forefront of the convergence between artificial intelligence and enzyme engineering. Our team comprises experts in computational biology, bioinformatics, and machine learning, all driven by a mission to accelerate innovation in enzyme design. By leveraging our advanced AI models, we provide unparalleled solutions that enhance efficiency, reduce costs, and push the boundaries of what's possible in enzyme engineering
Proud Member of Leading Global AI Programs
Neoncorte Bio is part of the NVIDIA Inception and Nebius for Startups programs — two of the world’s leading ecosystems for high-performance AI innovation. These partnerships strengthen our ability to deliver next-generation AI-driven protein, enzyme, and aptamer engineering.
  • NVIDIA Inception Neoncorte Bio AI life sciences company
    As a member of NVIDIA Inception, Neoncorte Bio gains access to cutting-edge GPU technologies, expert guidance, and a global AI ecosystem that supports companies from prototype to production. The program empowers us to explore new AI opportunities and build high-performance biological design pipelines powered by NVIDIA’s world-class platform.
  • Nebius AI life sciences Neoncorte Bio
    Through Nebius for Startups, we gain access to high-performance compute infrastructure optimized for large-scale AI workloads, along with hands-on technical guidance and a strong community of innovative AI companies. Nebius enables us to train and deploy complex biological models more efficiently — accelerating enzyme, protein, and aptamer design while supporting rapid scaling of our R&D pipelines.
Publications
Scientific Publication of Neoncorte Bio Team
  • Modification of natural enzymes to introduce new properties and enhance existing ones is a central challenge in bioengineering. This study is focused on the development of Taq polymerase mutants that show enhanced reverse transcriptase (RTase) activity while retaining other desirable properties such as fidelity, 5′-3′ exonuclease activity, effective deoxyuracil incorporation, and tolerance to locked nucleic acid (LNA)-containing substrates.
  • The transcriptomic data are being frequently used in the research of biomarker genes of different diseases and biological states. The most common tasks there are the data harmonization and treatment outcome prediction. Both of them can be addressed via the style transfer approach. Either technical factors or any biological details about the samples which we would like to control (gender, biological state, treatment, etc.) can be used as style components.
  • List of all Neoncorte Bio publications dedicated to Molecular Biology, Biotechnology, Artificial Intelligence and Artificial Neural Networks, published mostly by Nikolay Russkikh, CEO of Neoncorte Bio

Our Expertise in Action
With extensive experience in AI applications and software engineering tailored to the life sciences, we specialize in solving complex challenges and delivering innovative solutions for our customers. Our work demonstrates a deep understanding of cutting-edge technologies and their application in the real world.
Here are examples of the types of projects we have successfully delivered:
  • Automated NGS Data Analysis:
    Designed a production-grade solution for the automated processing, annotation, and analysis of Next-Generation Sequencing (NGS) data.
  • Single-Cell Data Integration:
    Built state-of-the-art tools for integrating multimodal single-cell data, achieving recognition for technical excellence.
  • Metagenomic Classification Algorithms:
    Developed advanced methods for classifying sequencing reads in metagenomics research.
  • High-Throughput Image Processing Pipelines:
    Engineered an efficient pipeline to process millions of sequencing images with exceptional accuracy.
  • Cell Counting via AI:
    Created a computer vision solution for precise cell counting in microphotography images, streamlining data analysis.
Get in touch with our team
Phone: +1-503-754-3958
Email: contact@neoncorte.com